button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessablestatistically conclusive-34%--
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 certainty unassessablestatistically conclusive-30%--
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 certainty unassessablestatistically conclusive-22%--
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessable-31%--
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-23%--
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 certainty unassessablestatistically conclusive-29%--

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons